__NUXT_JSONP__("/drugs/Anti-CTLA-4_Monoclonal_Antibody_REGN4659", (function(a,b,c,d){return {data:[{drug:{slug:b,emaEpar:[],fdaDrugLabel:[],id:b,nciThesaurus:{casRegistry:a,chebiId:a,chemicalFormula:a,definition:"A fully human immunoglobulin G1 (IgG1) antibody directed against the human T-cell-expressed receptor cytotoxic T-lymphocyte-associated antigen 4 (CTLA4; CTLA-4), with potential immune checkpoint inhibitory and antineoplastic activities. Upon intravenous administration, anti-CTLA-4 monoclonal antibody REGN4659 targets and binds to CTLA-4 expressed on T-cells and inhibits the CTLA-4-mediated downregulation of T-cell activation. This leads to a cytotoxic T-lymphocyte (CTL)-mediated immune response against cancer cells. CTLA-4, an inhibitory receptor and member of the immunoglobulin superfamily (IgSF), plays a key role in the downregulation of the immune system.",fdaUniiCode:"6CGQ1X5Y6V",identifier:"C159764",preferredName:c,semanticType:"Amino Acid, Peptide, or Protein",subclassOf:["C128036","C129822"],synonyms:[c,"REGN 4659","REGN-4659","REGN4659"]},dir:"\u002Fdrugs",path:"\u002Fdrugs\u002FAnti-CTLA-4_Monoclonal_Antibody_REGN4659",extension:".json",createdAt:d,updatedAt:d}}],fetch:{},mutations:void 0}}("","Anti-CTLA-4_Monoclonal_Antibody_REGN4659","Anti-CTLA-4 Monoclonal Antibody REGN4659","2021-10-30T13:34:57.293Z")));